欧林生物终止定增 拟现金买新诺明15%股权上市即巅峰

Core Viewpoint - 欧林生物 has decided to terminate its plan for a simplified procedure to issue A-shares to specific investors and has withdrawn the application due to current market conditions and company circumstances [1] Group 1: Termination of Share Issuance - The company held its seventh board meeting on August 29, 2025, where it approved the termination of the A-share issuance plan [1] - The decision was made after careful analysis of various factors, including market conditions and the company's development plans [1] - The termination of the share issuance will not significantly impact the company's daily operations or harm the interests of the company and its shareholders [1] Group 2: Previous Issuance Plan Details - The previous plan aimed to raise up to RMB 300 million, with a maximum of 20% of the company's net assets from the previous year [2] - The funds were intended for the vaccine research and production base renovation project, with a total investment of RMB 290 million [3] - The planned issuance involved 9,138,795 shares at a price of RMB 13.71 per share, representing up to 30% of the company's total share capital before the issuance [4] Group 3: Shareholder Structure and Control - Shanghai Wushan is the controlling shareholder, holding 17.83% of the company's shares, while the actual controllers are 樊绍文 and 樊钒, who collectively control 29.22% of the voting rights [5] - After the planned issuance, the actual controllers would hold 28.58% of the voting rights, indicating no change in control [5] Group 4: Acquisition of Minority Stake - The company plans to acquire a total of 15% of the minority shares in its subsidiary, 新诺明生物, through a public transfer at a price not exceeding RMB 45 million [6] - This acquisition does not constitute a major asset restructuring and does not involve related transactions [6]